-
公开(公告)号：WO2016201434A2
公开(公告)日：2016-12-15
申请号：PCT/US2016/037236
申请日：2016-06-13
Applicant: C2N DIAGNOSTICS, LLC
Inventor： JOHN, Elizabeth , VERGHESE, Philip , HU, Helen , KRON, Matthias , ZIPFEL, Katja , FAUDE, Alexander
IPC: A61K39/395
CPC classification number: C07K16/18 , A61K39/39591
Abstract: Provided herein are stable compositions containing anti-tau antibodies. In particular, compositions containing C2N-8E12 anti-tau antibody and a buffering system are provided herein.
Abstract translation: 本文提供含有抗tau抗体的稳定组合物。 特别地，本文提供了含有C2N-8E12抗tau抗体和缓冲系统的组合物。
-
2.发明申请METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES, DISORDERS AND ASSOCIATED PROCESSES 审中-公开诊断和治疗神经病学和神经病变疾病，疾病及相关过程的方法
公开(公告)号：WO2013043745A1
公开(公告)日：2013-03-28
申请号：PCT/US2012/056144
申请日：2012-09-19
Applicant: C2N DIAGNOSTICS
Inventor： WEST, Tim , PAOLETTI, Andrew C
IPC: A61B6/00 , G01N33/534 , G01T1/00
CPC classification number: G01N33/6896 , G01N2333/47 , G01N2500/04 , G01N2800/28 , G01N2800/2821 , G01N2800/2835 , G01N2800/2871 , G01N2800/52
Abstract: Methods for the diagnosis, prognosis, treatment and determining the efficacy of a therapeutic regimen for neurological and neurodegenerative diseases, disorders, and associated processes include using a detectable label to measure levels of alpha- synuclein.
Abstract translation: 用于诊断，预后，治疗和确定神经和神经变性疾病，病症和相关过程的治疗方案的功效的方法包括使用可检测标记物来测量α-突触核蛋白的水平。
-
公开(公告)号：WO2015200806A2
公开(公告)日：2015-12-30
申请号：PCT/US2015/038002
申请日：2015-06-26
Applicant: C2N DIAGNOSTICS LLC
Inventor： WEST, Tim , ATHWAL, Diljeet, S. , JONES, Timothy, D. , CARR, Francis, J. , HOLGATE, Robert, George, Edward
IPC: A61K51/10 , A61K39/395
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/92
Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.
Abstract translation: 本文提供了特异性结合tau的分离的抗体或抗原结合片段，所述抗体或片段包含重链可变（VH）区和具有本文列出的氨基酸序列的轻链可变（VL）区。 还提供了预防或治疗受试者中的tau蛋白病的方法，其包括向需要治疗的人用一种或多种如本文所述的抗体或片段进行tau蛋白病治疗的患者，其中所述抗体或抗原结合片段在条件和 以有效预防或治疗tau病变的量。
-
4.发明申请
公开(公告)号：WO2018231415A1
公开(公告)日：2018-12-20
申请号：PCT/US2018/032901
申请日：2018-05-16
Applicant: C2N DIAGNOSTICS LLC
Inventor： MEYER, Matthew, Richard
Abstract: Extraction and separation methods that can be used to quantify the absolute concentrations of one or more low abundance biomolecules present in biological fluids and tissues, without the need for antibody enrichment or reliance on an antibody for quantification are provided. These biomolecules can be biomarkers used to diagnose and monitor disease progression. As an example, these methods are applied to human plasma and CSF, and used to quantify Alzheimer's disease biomarkers.
-
Patent Agency Ranking
公开(公告)号：WO2018148593A1
公开(公告)日：2018-08-16
申请号：PCT/US2018/017691
申请日：2018-02-09
Applicant: C2N DIAGNOSTICS, LLC
Inventor： KIRMESS, Kristopher, M. , YARASHESKI, Kevin, E. , MEYER, Matthew, R.
Abstract: The present invention provides methods for measuring the absolute concentration of Tau, and other protein, peptide fragments and proteoforms in CSF and plasma samples collected from a subject. Such biomoiecuies may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the CSF or plasma concentration of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.
-
公开(公告)号：WO2016201434A3
公开(公告)日：2017-02-09
申请号：PCT/US2016037236
申请日：2016-06-13
Applicant: C2N DIAGNOSTICS LLC
Inventor： JOHN ELIZABETH , VERGHESE PHILIP , HU HELEN , KRON MATTHIAS , ZIPFEL KATJA , FAUDE ALEXANDER
IPC: A61K39/395 , A61P25/28 , C07K16/18
CPC classification number: C07K16/18 , A61K39/39591
Abstract: Provided herein are stable compositions containing anti-tau antibodies. In particular, compositions containing C2N-8E12 anti-tau antibody and a buffering system are provided herein.
Abstract translation: 本文提供含有抗tau抗体的稳定组合物。 特别地，本文提供了含有C2N-8E12抗tau抗体和缓冲系统的组合物。
-
公开(公告)号：WO2015200806A3
公开(公告)日：2016-02-25
申请号：PCT/US2015038002
申请日：2015-06-26
Applicant: C2N DIAGNOSTICS LLC
Inventor： WEST TIM , ATHWAL DILJEET S , JONES TIMOTHY D , CARR FRANCIS J , HOLGATE ROBERT GEORGE EDWARD
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/92
Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.
Abstract translation: 本文提供了特异性结合tau的分离的抗体或抗原结合片段，所述抗体或片段包含重链可变（VH）区和具有本文列出的氨基酸序列的轻链可变（VL）区。 还提供了预防或治疗受试者中的tau蛋白病的方法，其包括对需要治疗与本文所述的一种或多种抗体或片段的tau蛋白病进行治疗的人，其中所述抗体或抗原结合片段在条件和 以有效预防或治疗tau病变的量。
-
公开(公告)号：WO2013082307A1
公开(公告)日：2013-06-06
申请号：PCT/US2012/067110
申请日：2012-11-29
Applicant: C2N DIAGNOSTICS
Inventor： WEST, Tim , PAOLETTI, Andrew, Corey
IPC: G01N33/483
CPC classification number: G01N33/6896 , G01N33/5308 , G01N33/6893 , G01N2333/47 , G01N2458/15 , G01N2560/00 , G01N2800/28 , G06F19/20
Abstract: The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.
Abstract translation: 本发明提供了测量受试者感兴趣的生物分子的绝对浓度的方法。 这样的生物分子可能涉及一种或多种神经和神经变性疾病或病症。 还提供了一种用于确定治疗剂是否影响衍生的中枢神经系统生物分子的体内代谢的方法。 还提供了用于实施本发明的方法的试剂盒。
-
公开(公告)号：WO2010065878A1
公开(公告)日：2010-06-10
申请号：PCT/US2009/066810
申请日：2009-12-04
Applicant: C2N DIAGNOSTICS , WEST, Tim , PAOLETTI, Andrew, Corey
Inventor： WEST, Tim , PAOLETTI, Andrew, Corey
CPC classification number: G01N33/6896 , G01N33/537 , G01N33/58 , G01N2496/00
Abstract: The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.
Abstract translation: 本发明提供了测量受试者感兴趣的生物分子的绝对浓度的方法。 这样的生物分子可能涉及一种或多种神经和神经变性疾病或病症。 还提供了一种用于确定治疗剂是否影响衍生的中枢神经系统生物分子的体内代谢的方法。 还提供了用于实施本发明的方法的试剂盒。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.012 seconds)
